Friday, September 22, 2023
This article is intended for primary care clinicians, oncologists, hematologists, urologists, and other specialists who care for patients with metastatic testicular tumors.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 200 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/06. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity. AAFP credit is subject to change based on topic selection throughout the accreditation year.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CME Released: 7/27/2007
Valid for credit through: 7/27/2008, 11:59 PM EST
processing....
July 27, 2007 — The administration of high-dose chemotherapy plus hematopoietic stem-cell rescue can potentially provide a cure for testicular cancer, even when used as a third-line option or in patients with disease that is platinum refractory. This finding is reported in a retrospective review in the July 26 issue of the New England Journal of Medicine.
"Testis cancer is unique," lead investigator Lawrence E. Einhorn, MD, a distinguished professor and Lance Armstrong Foundation professor of oncology at Indiana University School of Medicine in Indianapolis, told Medscape. "There are few if any other types of cancer in which there is any realistic chance for cure after failing to be cured with prior chemotherapy."
Cisplatin-based chemotherapy has been shown to be curative in 79% of patients with newly diagnosed metastatic germ-cell cancers, but it is less well-established what factors are associated with long-term survival following salvage therapy. Candidates for salvage therapy are those with tumors that progress despite initial treatment or who relapse. In this study, the goal of the researchers was to examine the efficacy of high-dose carboplatin plus etoposide plus rescue hematopoietic peripheral blood stem-cell rescue, in patients with cisplatin-resistant, progressively growing testicular cancer.
Dr. Einhorn and colleagues reviewed the cases of 184 patients with metastatic testicular cancer whose disease had progressed despite treatment with cisplatin-containing combination chemotherapy. The patients had all received high-dose chemotherapy and peripheral blood stem-cell rescue between February 1996 and December 2004. The regimen consisted of 700 mg of carboplatin per square meter of body surface area plus 750 mg of etoposide per square meter, which were administered 5, 4, and 3 days prior to an infusion of stem cells.
"High dose chemo is our first option for patients who fail to be cured with standard dose chemotherapy," Dr. Einhorn told Medscape. "Some centers will instead use standard dose platinum combination chemotherapy with cisplatin plus ifosfamide, and either vinblastine or paclitaxel and reserve high dose chemo, if needed, for 3rd line chemotherapy."
At a median follow-up of 48 months, 116 (63%) of the cohort had remained continuously free of disease. Of this group, 104 (90%) were disease free for more than 2 years. A complete remission was observed in 6 additional patients; 4 patients experienced a remission after receiving paclitaxel plus gemcitabine, and 2 patients had a remission after they underwent a subsequent germ-cell tumor resection.
The researchers found that certain variables were significantly associated with progression-free survival. These included the use of high-dose chemotherapy as a second-line agent as compared with third-line chemotherapy, the tumor response to cisplatin, the response to initial chemotherapy, a favorable International Germ Cell Cancer Collaborative Group (IGGCCG) score, and favorable prognostic features.
A further breakdown of survival showed that of the 61 patients with favorable prognostic features, 49 experienced a continuous period of remission for a median of 46 months. In the subgroup of 40 patients with progressive metastatic disease and platinum-refractory tumors, 18 remained disease free for a median of 49 months.
Grade 3 or higher toxic adverse effects developed in 55 patients following high-dose chemotherapy. The most common were gastrointestinal related, but 3 patients developed leukemia with 2 subsequent deaths. Three other patients experienced sudden drug-related deaths, in which 2 were caused by hepatic failure and the third from toxic pulmonary effects.
"The key point of this study is that even after going through a difficult course of initial chemotherapy and experiencing a relapse of the cancer, there is still a high probability for a cure with salvage chemotherapy using high dose chemotherapy," said Dr. Einhorn. "Our other key point is that is was possible to overcome drug resistance to standard doses of platinum plus etoposide with high dose chemo, as 18 of 40 of patients who progressed within 4 weeks of their last course of standard dose chemotherapy were cured with high dose chemotherapy."
N Engl J Med. 2007;357:340-348.
